DK Life Science Co., Ltd. (KOSDAQ:303810)
South Korea flag South Korea · Delayed Price · Currency is KRW
2,210.00
-10.00 (-0.45%)
Sep 14, 2026, 2:27 PM KST

DK Life Science Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
117,747130,344131,816120,161107,234102,668
Revenue Growth
-12.22%-1.12%9.70%12.05%4.45%-6.31%
Gross Profit
29,78132,98628,57525,25322,17121,842
Operating Income
10,19113,04511,9168,5306,2306,797
Net Income
4,9758,6582,2454,1674,2395,858
Earnings Per Share
155.07274.6880.00372.003787.005233.00
EPS Growth
-38.79%243.35%-78.50%-90.18%-27.63%34.25%

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
8,3237,2544,5533,8744,5318,223
Total Debt
37,79338,98345,23047,64541,80423,413
Net Cash (Debt)
-29,471-31,730-40,676-43,771-37,274-15,190
Net Cash Growth
------
Net Cash Per Share
-918.61-1006.61-1449.67-3907.82-33296.60-13570.02

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
8,379433.6511,536-4,608-2,916-1,424
Capital Expenditures
-7,165-5,691-5,081-4,791-17,371-23,315
Free Cash Flow
1,214-5,2576,455-9,398-20,287-24,739
Free Cash Flow Growth
-60.97%-----

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
25.29%25.31%21.68%21.02%20.68%21.27%
Operating Margin
8.65%10.01%9.04%7.10%5.81%6.62%
Pretax Margin
5.34%8.31%3.61%4.02%4.92%6.27%
Profit Margin
4.23%6.64%1.70%3.47%3.95%5.71%
FCF Margin
1.03%-4.03%4.90%-7.82%-18.92%-24.10%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
14.3213.52----
PS Ratio
0.600.90----